KT-621: BROADEN2 Phase 2b Trial
Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Dose-ranging
                                Design
                                • Randomized, double-blind,
                                  placebo-controlled
                                                                            Key Trial Aim
                                • ~200 patients
                                • Daily dose for 16-weeks;                  Establish clinical activity and
  Adult & Adolescent              52-week open label extension
                                                                            safety in AD to select Phase 3
  Moderate to Severe            Dosing                                      dose to support registrational
     AD Patients                • Three KT-621 doses + one placebo          studies in multiple dermatological
     Ages 12-75                   (1:1:1:1)                                 and gastrointestinal indications
                                Endpoints
 Baseline entry criteria:       • Primary endpoint: Percent change
       EASI ≥ 16;                 from baseline in EASI score             Status update:
     vIGA-AD ≥ 3;                 at week 16
 Peak Pruritus NRS ≥4;                                                    Ongoing, also including
                                • Secondary endpoints include:
       BSA ≥10%;
                                   • EASI-50, EASI-75, vIGA-AD 0/1
                                                                          adolescents;
   Documented TCS
                                   • At least a 4-point improvement       Data expected by mid-2027
     failure for AD
                                     from baseline in Peak Pruritus NRS

                                                                                                            19
